Clinical Effects of Simvastatin in Patients with Hypercholesterolemia.
10.4070/kcj.1997.27.4.417
- Author:
Myung Ho JEONG
;
Kwang Soo CHA
;
Jong Cheol PARK
;
Jeong Pyung SEO
;
Joo Hyung PARK
;
Jeong Gwan CHO
;
Jin Gyoon PARK
;
Soon Pal SUH
;
Jong Chun PARK
;
Jung Chaee KANG
- Publication Type:Original Article
- Keywords:
Simvastatin;
Hypercholesterolemia;
Apolipoprotein;
Lipoprotein(a)
- MeSH:
Apolipoprotein A-I;
Apolipoproteins;
Apolipoproteins B;
Chest Pain;
Cholesterol;
Creatine Kinase;
Creatinine;
Exanthema;
Humans;
Hypercholesterolemia*;
Lipoprotein(a);
Lipoproteins;
Male;
Oxidoreductases;
Simvastatin*
- From:Korean Circulation Journal
1997;27(4):417-425
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: To evaluate the clinical efficacy of Simvastatin, a HMG-CoA reductase inhibitor, We ibsweved the changes of clinical characteristics and lipid profiles after Simvastatin administration in patients with hypercholesterolemia. METHODS AND RESULTS: Simvastatin 10mg was given once daily for 12 weeks in 35 patients (60+/-6.0 years : 14 male, 21 female) with hypercholesterolemia. High density lipoprotein-cholesterol (HDL-C) was increased from 38+-10 to 45+-9mg/dl(p<0.05). Simvastatin significantly decreased total cholesterol(TC) from 235+-15 to 181+-21mg/dl(23.0%), low-density lipoprotein cholesterol (LDL-C) from 164+-19 to 104+-18mg/dl(36.5%), TC/HDL-C from 7.0+-2.0 to 4.4+-1.1, LDL-C/HDL-C from 4.9+-1.7 to 2.5+-0.8(p<0.01 respectively). Apo B was decreased by 31%(119+-19 to 87+-15mg/dl), apo B/A1 ratio was decreased by 41%(1.2+-0.2 to 0.7+-0.2) amd lipoprotein(a) edcreased by 12%(33+-22 to 29+-17), while apo A1 was increased by 25%(104+-18 to 130+-23mg/dl, p<0.01 respectively). No patients complained of chest pain, but two had skin rashes. Creatine kinase and creatinine were not changed in all patients. CONCLUSIONS: Somvastatin is an effective and well tolerated cholesterol lowering agent in patients with hypercholesterolemia.
